Clinical Trial Update: A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) [Phase 3]

View source ↗

Summary

Phase 3 study comparing once-daily darunavir/ritonavir 800 mg/100 mg to twice-daily 600 mg/100 mg in early treatment-experienced HIV-1 infected patients; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Human Immunodeficiency Virus - Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2010-09-22